Startups
Draig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders’ unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD). Draig is the Welsh word for ‘dragon’ and it reflects the company’s origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University.
Overview
Location
United Kingdom
Total raised
$65M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 14, 2026 | Draig Therapeutics Raises $65M in Series B Funding | Draig Therapeutics, a Cardiff, Wales, UK-based clinical-stage biopharmaceutical company developing neuropsychiatric therapies, raised $65M in Series B funding. The round was led by Deep Track Capital with participation from Janus Henderson ... |
| Jul 14, 2026 | Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders | Financing led by new investor, Deep Track Capital with participation from Janus Henderson Investors and Marshall Wace among other investors Proceeds will support accelerated clinical advancement of company’s pipeline, including lead program... |
| Oct 2, 2025 | Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder | • DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety • Phase 2 clinical trial initiation anticipated before the end of 2025 • Trial builds on positive Phase 1 study that showed DT-101 was well ... |
| Jun 19, 2025 | Schroders Capital UK Innovation LTAF Announces Biopharma Investment | Listen to this article 0:00 / 1:02 1X BeyondWords Schroders Capital, the $99.3bn private markets business of Schroders, announces today that its UK Innovation Long-Term Asset Fund (LTAF) has invested in Draig Therapeutics, a clinical-stage ... |
| Jun 18, 2025 | Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders | Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million)... |
| Jun 18, 2025 | Neuropsychiatry biotech Draig Therapeutics hatches with red-hot $140M series A | A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in major depressive disorder. Draig Therapeutics has emerged from a partnership between Cardiff University’s Medicine... |
| Draig Therapeutics | “Draig” |
Reviews 0
FAQ about Draig Therapeutics
How much funding has Draig Therapeutics raised?
Draig Therapeutics has raised $65M in total across 1 funding round.
What has the press written about Draig Therapeutics?
Parsers VC has collected 8 articles mentioning Draig Therapeutics, among them “Draig Therapeutics Raises $65M in Series B Funding” (Jul 14, 2026) and “Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychia...” (Jul 14, 2026).
Is Draig Therapeutics still active?
Yes, Draig Therapeutics is active; its latest activity on Parsers VC dates from Jul 14, 2026.